

PRESSURE BIOSCIENCES INC  
Form 8-K  
May 01, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant**

**to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) April 25, 2019

**PRESSURE BIOSCIENCES, INC.**

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

(State or Other Jurisdiction of Incorporation)

001-38185 04-2652826  
(Commission (IRS Employer

File Number) Identification No.)

14 Norfolk Avenue, South Easton, MA 02375  
(Address of Principal Executive Offices) (Zip Code)

(508) 230-1828

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**Departure of Officer and Designation of Successor**

On April 25, 2019, Mr. Richard T. Schumacher, President and Chief Executive Officer (“CEO”) of Pressure BioSciences, Inc. (the “Company”) informed the Company’s Board of Directors (the “Board”) that he plans to step down as President and CEO, effective September 9, 2019. Mr. Schumacher is expected to continue to serve as a member of the Board. After September 9, 2019, Mr. Schumacher is expected to serve as a senior consultant to the Company for at least one year.

On May 1, 2019, the Company announced that the Board has designated Bradford A. Young, Ph.D., MBA to succeed Mr. Schumacher as the Company’s President and CEO, effective September 9, 2019. Dr. Young has been the Company’s Senior Vice President and Chief Commercial Officer since November 2018. A copy of the press release announcing Mr. Schumacher’s transition to a new role and Dr. Young’s designation is furnished as Exhibit 99.1 to this report.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

**Exhibit Description**

**Number**

99.1 Press release issued by Pressure BioSciences, Inc. dated May 1, 2019.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 1, 2019 **PRESSURE BIOSCIENCES, INC.**

By: */s/ Richard T. Schumacher*  
Richard T. Schumacher,  
President and Chief Executive Officer

